Pfizer’s InnoPharma unit finally overcame US FDA’s concerns about injectable acetaminophen GMPs and leachables. Meanwhile, Azurity resolved zonisamide manufacturing issues, Amphastar overcame doubts about naloxone’s nasal spray device, Incyte reused Zynyz CMC data, Cidara showed Rezzayo vials had enough powder, Pharming showed equivalence between Joenja tablets and capsules, and Orphalan avoided half-tablet stability testing of its functionally scored Cuvrior tablets.

As the Kingdom of Saudi Arabia reduces its dependence on oil as an export, one sector it is building up is the life sciences industry. The government is encouraging global companies to manufacture and invest domestically and they are improving their regulatory system and working with local players to enhance access to patients.

After a tough 2022 that saw Hikma suffer an 18% drop in generics sales – albeit mostly offset by growth in the firm’s injectables and branded divisions – the company has announced fresh forecasts for 2023 that suggest the generics segment will bounce back with growth of a fifth.

Hikma’s president of injectables, Riad Mishlawi, has been chosen to become the firm’s new CEO from the start of September. The move comes after a period of success in injectables for Hikma, at the same time as the firm attempts to revive the fortunes of its generics business.